Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment

Alice Boilève; Armelle Dufresne; Ali N. Chamseddine; Elise F. Nassif; Sarah Dumont; M. Brahmi; Julien Adam; Etienne Rouleau; Marie Karanian; Véronique Haddad; Matthieu Faron; Charles Honoré; Pierre Méeus; Axel Le Cesne; Jean‐Yves Blay; Olivier Mir

doi:10.1136/esmoopen-2020-001082

JOURNAL ARTICLE

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment

Alice Boilève Armelle Dufresne Ali N. Chamseddine Elise F. Nassif Sarah Dumont M. Brahmi Julien Adam Etienne Rouleau Marie Karanian Véronique Haddad Matthieu Faron Charles Honoré Pierre Méeus Axel Le Cesne Jean‐Yves Blay Olivier Mir

Year: 2020 Journal: ESMO Open Vol: 5 (6)Pages: e001082-e001082 Publisher: Elsevier BV

DOI: 10.1136/esmoopen-2020-001082

Get Full-Text PDF Get Analytical Report

Keywords:

Dasatinib GiST Medicine Nilotinib Imatinib Internal medicine PDGFRA Oncology Progression-free survival Imatinib mesylate Stromal tumor Tyrosine-kinase inhibitor Gastroenterology Stromal cell Chemotherapy Cancer

Metrics

Cited By

0.41

FWCI (Field Weighted Citation Impact)

Refs

0.61

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Gastrointestinal Tumor Research and Treatment

Health Sciences → Medicine → Gastroenterology

Gastric Cancer Management and Outcomes

Health Sciences → Medicine → Pulmonary and Respiratory Medicine

Neurofibromatosis and Schwannoma Cases

Health Sciences → Medicine → Neurology

Related Documents

JOURNAL ARTICLE

Outcomes of patients (pts) with advanced gastro-intestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib (IM) as first-line treatment.

Alice Boilève Armelle Dufresne Ali N. Chamseddine Sarah Dumont M. Brahmi Julien Adam Etienne Rouleau Marie Karanian Véronique Haddad Matthieu Faron Charles Honoré Pierre Méeus Axel Le Cesne Jean‐Yves Blay Olivier Mir

Journal: Journal of Clinical Oncology Year: 2020 Vol: 38 (15_suppl)Pages: 11532-11532

JOURNAL ARTICLE

Clinical prognostic factors in metastatic gastrointestinal stromal tumors (GIST) patients treated with Imatinib

Antonio López–Pousa Óscar Gallego Xavier Matías‐Guiu Rosa Nadal R Pinedo Villanueva Miguel Quintana Gemma Carrera Raquel Marsé Vicenç Artigas Agustí Barnadas

Journal: Journal of Clinical Oncology Year: 2006 Vol: 24 (18_suppl)Pages: 19500-19500

JOURNAL ARTICLE

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors

Mark Fairweather Vinod P. Balachandran George Z. Li Monica M. Bertagnolli Cristina R. Antonescu William D. Tap Samuel Singer Ronald P. DeMatteo Chandrajit P. Raut

Journal: Annals of Surgery Year: 2017 Vol: 268 (2)Pages: 296-302

JOURNAL ARTICLE

Real-Life Management of advanced Gastrointestinal Stromal Tumors (GIST) Treated with Imatinib in France

Olivier Bouché Axel Le Cesne M. Rios L. Chaigneau B. Bui Pérez Candel Xavier Jean‐Yves Blay

Journal: Annals of Oncology Year: 2012 Vol: 23 Pages: ix236-ix236

JOURNAL ARTICLE

Unlike CML Patients, Patients with Gastrointestinal Stromal Tumors (GIST) Treated with Imatinib Do Not Develop Hematopoietic Clonal Cytogenetic Abnormalities.

Manuel Abecasis Pedro Lage Maria Salazar João Freire António Moreira Margarida Mendes Jorge Helena Alaiz

Journal: Blood Year: 2004 Vol: 104 (11)Pages: 4702-4702